Soleno Therapeutics appoints Jennifer Fulk as CFO, succeeding retiring James Mackaness

SOLENO THERAPEUTICS INC

Jennifer Fulk appointed CFO effective March 2, 2026; base salary $525k, target bonus 45%, option for 67,660 shares, RSUs for 39,200 shares.
James Mackaness retiring by end of March 2026, will consult through December 2026 for smooth transition.
Fulk brings 20+ years experience including 15 years at Eli Lilly, most recently CFO/COO at 120Water and CFO at Talkspace.
Fulk will participate in Soleno's Key Executive Change in Control and Severance Plan.

item 5.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.